BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24260311)

  • 21. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
    Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
    Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lee MS; Liu CY; Su L; Christiani DC
    Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
    Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
    PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
    Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies.
    Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y
    J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.
    Zhang X; Jiang LP; Yin Y; Wang YD
    Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphisms of xeroderma pigmentosum group D and prostate cancer risk: a meta-analysis.
    Zhu H; Cao S; Liu Y; Ding X; Wu Q; Ma H
    J Cancer Res Ther; 2013; 9(2):187-92. PubMed ID: 23771356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
    Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
    Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
    Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.